A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HSK47388 in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 10 Mar 2026
At a glance
- Drugs HSK 47388 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 05 Mar 2026 Status changed from not yet recruiting to recruiting.
- 21 Jan 2026 New trial record